Intraocular Melanoma Treatment Market Size, Share, Trends & Forecast
The Intraocular Melanoma Treatment Market is evolving as advances in ocular oncology create more options for managing melanoma originating within the eye. Treatment strategies depend on tumor characteristics and disease stage, with established approaches including plaque brachytherapy, proton beam radiotherapy, surgery, and newer systemic therapies.
Radiation-based treatments remain an important part of primary disease management. Plaque brachytherapy can help preserve the eye in suitable patients, while proton beam radiotherapy provides another specialized option for controlling localized tumors. These approaches are increasingly supported by treatment planning and imaging technologies that help clinicians target tumors more precisely.
The treatment landscape is also changing for patients with advanced disease. Tebentafusp has introduced a more specialized systemic treatment option for HLA-A*02:01-positive adults with unresectable or metastatic uveal melanoma, creating a new segment within the broader intraocular melanoma treatment industry.
Future development is expected to focus on improving local tumor control while limiting damage to vision and surrounding ocular structures. Researchers are also investigating targeted therapies, immunotherapy combinations, and neoadjuvant approaches, creating opportunities for pharmaceutical companies and specialized oncology centers.